Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:45am, Tuesday, 13'th Jan 2026
Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
10:36am, Monday, 12'th Jan 2026
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 a
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Friday, 09'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
09:50am, Thursday, 08'th Jan 2026
Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.
2 Healthcare Stocks to Buy for 2026 and Beyond
05:15am, Thursday, 08'th Jan 2026
Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
08:00am, Wednesday, 07'th Jan 2026
ALAMEDA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
04:05pm, Tuesday, 06'th Jan 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview
See How Rare Bullish Inflows Lift Outliers Like Exelixis
12:46pm, Wednesday, 31'st Dec 2025
Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, is up 81% since a Big Money boost starting in 2021.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:45am, Wednesday, 31'st Dec 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:50am, Tuesday, 30'th Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cwm LLC Buys 48,496 Shares of Exelixis, Inc. $EXEL
04:51am, Tuesday, 30'th Dec 2025
Cwm LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ: EXEL) by 32.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1
Osaic Holdings Inc. Raises Position in Exelixis, Inc. $EXEL
05:13am, Saturday, 27'th Dec 2025
Osaic Holdings Inc. increased its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 151.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commi
Exelixis, Inc. $EXEL Shares Sold by Burney Co.
04:28am, Saturday, 27'th Dec 2025
Burney Co. lowered its stake in Exelixis, Inc. (NASDAQ: EXEL) by 43.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 230,1
Exelixis, Inc. (NASDAQ:EXEL) Given Consensus Rating of “Moderate Buy” by Brokerages
03:24am, Sunday, 21'st Dec 2025
Shares of Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-seven research firms that are currently covering the firm, Marketbeat.c
